MedPath

A Study to Learn How Well Mirena Works as Compared to Oral Progestin in Nonatypical Endometrial Hyperplasia in Women Who Have Started Their Periods

Phase 3
Not yet recruiting
Conditions
Endometrial Hyperplasia
Interventions
Combination Product: BAY865028
Registration Number
NCT06904274
Lead Sponsor
Bayer
Brief Summary

Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).

Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.

Currently, oral progestins (OP) which are progesterone (female hormone) capsules taken by mouth, are used to treat NAEH. However, there is still a need for other treatments due to unmet needs.

The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.

In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.

The main purpose of this study is to learn how well Mirena works compared to oral in NAEH in women who have started their periods.

For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral progestins.

The study participants will be randomly divided equally into one of two treatment groups. Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.

Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site.

Participants will visit the study clinic:

* once before the treatment starts

* 3 times with a gap of 3 months between the visits during the treatment

* then 1 more time after the treatment ends

During the study, the doctors and their study team will:

* check participant's health by performing tests such as blood and urine tests

* perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.

* take samples of womb (endometrial) lining

* ask the participants questions about how they are feeling and what adverse events they are having

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
300
Inclusion Criteria
  • Post-menarchal women (≥ 16-years) at the time of signing the informed consent.
  • Women with histologically confirmed NAEH independent of their parity or menopausal status.
Exclusion Criteria
  • Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results.
  • Congenital or acquired uterine or cervical anomaly including fibroids, or cervical stenosis that in the opinion of the investigator, would interfere with insertion and/or retention of the intrauterine system (i.e., if they distort the uterine cavity).
  • Use of any long-acting injectable sex-hormone preparations within 6 months prior to the start of study intervention, and /or short acting hormonal medication within 6 weeks prior to the start of study intervention.
  • Pregnancy
  • Participants with either known family or personal history of genetic predisposition to uterine, ovarian or colorectal cancers (e.g. Lynch syndrome).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Levonorgestrel (BAY865028, Mirena)BAY865028Mirena will be inserted into the participant's uterus by the investigator on Day 1. At visit 4 (after 6 months) or if a participant discontinues her study participation prematurely, the Mirena will be removed by the investigator.
Oral progestinMedroxyprogesterone acetateParticipants will receive 10mg oral progestin once daily, preferably always at the same time of the day, until visit 4 (after 6 months).
Primary Outcome Measures
NameTimeMethod
Proportion of participants with Complete Resolution (CR) of NAEHAt 6 months

Complete Resolution will be evaluated as benign endometrium.

Secondary Outcome Measures
NameTimeMethod
Recurrence of NAEH after CRAt 3 months follow up after 6 months treatment

Recurrence of NAEH on 3 months treatment free after CR at 6 months

Progression after CRAt 3 months follow up after 6 months treatment

Endometrial hyperplasia with atypia or endometrial cancer after 3 months treatment free follow up after CR at 6 months

Proportion of participants having hysterectomyDuring treatment and 3 months follow up
Diagnosis of "benign endometrium"At 6 months of treatment followed by 3 month treatment-free follow up
Number of participants with adverse eventsFrom the signing of the informed consent form (ICF) up to 3 months after the last dose of study intervention

All AEs will be coded using the latest version prior to database lock of the Medical Dictionary for Regulatory Activities

Trial Locations

Locations (54)

Chongqing Maternal and Child Health Care Hospital

🇨🇳

Chongqing, China

Axia Women's Health

🇺🇸

Oaks, Pennsylvania, United States

AMR - Mobile, AL

🇺🇸

Mobile, Alabama, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Women's Health Alliance of Mobile

🇺🇸

Mobile, Alabama, United States

Mesa Obstetricians and Gynecologists | Research Department

🇺🇸

Mesa, Arizona, United States

Cornerstone Clinic for Women

🇺🇸

Little Rock, Arkansas, United States

Velvet Clinical Research

🇺🇸

Burbank, California, United States

Allen Clinical Research LLC

🇺🇸

Gardena, California, United States

University of California Davis Medical Center

🇺🇸

Sacramento, California, United States

AMR - Fort Myers, FL

🇺🇸

Fort Myers, Florida, United States

University of Florida

🇺🇸

Gainesville, Florida, United States

Sweet Hope Research Specialty, Inc. | Hialeah, FL

🇺🇸

Hialeah, Florida, United States

Emerald Coast Clinical Research

🇺🇸

Panama City, Florida, United States

Physician Care Clinical Research LLC | Sarasota, FL

🇺🇸

Sarasota, Florida, United States

Piedmont Hospital

🇺🇸

Atlanta, Georgia, United States

Clinical Research Prime

🇺🇸

Idaho Falls, Idaho, United States

Women's Healthcare Associates, PA

🇺🇸

Idaho Falls, Idaho, United States

Office of Dr. Cindy Basinski, LLC

🇺🇸

Newburgh, Indiana, United States

McFarland Clinic

🇺🇸

Ames, Iowa, United States

Velocity Clinical Research - Lafayette

🇺🇸

Lafayette, Louisiana, United States

Southern Clinical Research Associates | Metairie, LA

🇺🇸

Metairie, Louisiana, United States

Gynecologic Oncology Associates

🇺🇸

Shreveport, Louisiana, United States

Omni Fertility and Laser Institute

🇺🇸

Shreveport, Louisiana, United States

Johns Hopkins Outpatient Center - Obstetrics and Gynecology

🇺🇸

Baltimore, Maryland, United States

Revive Research Institute, Inc. - Women's Health

🇺🇸

Dearborn Heights, Michigan, United States

St. Dominic's Gynecology/Oncology

🇺🇸

Jackson, Mississippi, United States

McGill Family Practice

🇺🇸

Papillion, Nebraska, United States

Affiliated Clinical Research, Inc. | Las Vegas, NV

🇺🇸

Las Vegas, Nevada, United States

Rutgers Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

Bosque Women's Care | Albuquerque, NM

🇺🇸

Albuquerque, New Mexico, United States

Montefiore Medical Park - Eastchester - OBGYN

🇺🇸

Bronx, New York, United States

Reply OBGYN and Fertility PLLC

🇺🇸

Durham, North Carolina, United States

Unified Women's Clinical Research | Raleigh, NC

🇺🇸

Raleigh, North Carolina, United States

Unified Women's Clinical Research

🇺🇸

Winston-Salem, North Carolina, United States

ClinOhio Research Services, LLC. | Columbus, OH

🇺🇸

Columbus, Ohio, United States

OB/GYN Associates of Erie

🇺🇸

Erie, Pennsylvania, United States

Galen Obstetrics And Gynecology Ridgeside

🇺🇸

Chattanooga, Tennessee, United States

South Texas Clinical Research

🇺🇸

Corpus Christi, Texas, United States

Discovery Clinical Trials - Dallas

🇺🇸

Dallas, Texas, United States

Advances in Health, INC. | Houston, TX

🇺🇸

Houston, Texas, United States

UT Health San Antonio - UT Health Medical Arts & Research Center (MARC)

🇺🇸

San Antonio, Texas, United States

The Woman's Place - Midlife Health

🇺🇸

Charlottesville, Virginia, United States

Inova Fairfax Hospital - OBGYN

🇺🇸

Falls Church, Virginia, United States

Xiamen Maternity and Child Health Care Hospital

🇨🇳

Xiamen, Fujian, China

Nanjing Maternity and Child Health Care Hospital

🇨🇳

Nanjing, Jiangsu, China

Jiangxi Maternal and Child Health Hospital

🇨🇳

Nanchang, Jiangxi, China

Women and Children's Hospital, Qingdao University

🇨🇳

Qingdao, Shandong, China

Chengdu Women & Children's Central Hospital

🇨🇳

Chengdu, Sichuan, China

Women's Hospital School of Medicine Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

China-Japan Friendship Hospital

🇨🇳

Beijing, China

Peking Union Medical College Hospital CAMS

🇨🇳

Beijing, China

Nanjing Medical University (NMU) - The Second Affiliated Hospital

🇨🇳

Nanjing, China

Tangshan Maternal and Child Health Care Hospital

🇨🇳

Tangshan, China

© Copyright 2025. All Rights Reserved by MedPath